|
NetScientific PLC on Wednesday said its portfolio company PDS Biotechnology Corporation had reported a median overall survival of 21 months in its phase 2 clinical trial of PDS0101 triple combination.
The London-based healthcare IP commercialisation firm said the PDS0101-based triple-combination therapy showed a median OS of 21 months in 29 checkpoint inhibitor refractory patients, all of whom had failed prior chemotherapy treatment.
The historical median OS in patients with CPI refractory disease is three to four months, the company said.
PDS is a New Jersey-based clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease.
NetScientific said 75% of CPI naive subjects remain alive at a median follow-up of 27 months, and median OS has not been yet been reached. The historical median OS for similar patients is 7-11 months.
PDS Chief Executive Officer Frank Bedu-Addo said: ‘The expanded data continue to demonstrate the durability and tolerability of the PDS0101-based triple combination therapy in advanced HPV-positive cancers, an extremely challenging population of refractory and previously untreatable HPV-positive patients.’
PDS0101 is being studied in CPI-naïve and CPI-refractory patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar cancers.
NetScientific shares were up 4.7% trading at 67.30 pence per share late on Wednesday afternoon in London.
By Harvey Dorset, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.
|
